Nektar Therapeutics Investor Presentation — January 2020

Document content

J.P . Morgan Healthcare Conference

January 13, 20202This presentation includes forward -looking statements regarding Nektar’s proprietary drug

candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing

and outcome of regulatory decisions, and future availability of clinical trial data. Actual results

could differ materially and these statements are subject to important risks detailed in Nektar's

filings with the SEC including the Form 10 -Q filed on November 7, 2019. Nektar undertakes no

obligation to update forward -looking statements as a result of new information or otherwise.A Robust Pipeline in Multiple Therapeutic Areas

Systemic Lupus Erythematosus NKTR -358

Atopic Dermatitis NKTR -358Chronic Low Back Pain NKTR -181

Metastatic Melanoma Bempegadesleukin (bempeg ) + OPDIVO®

Renal Cell Carcinoma Bempeg + OPDIVO®

Muscle -invasive Bladder Cancer Bempeg + OPDIVO®

Bladder Cancer Bempeg + OPDIVO®

1L NSCLC Bempeg + KEYTRUDA®

Head & Neck SCC Bempeg + Pfizer compounds

Metastatic Prostate Cancer Bempeg + Pfizer compounds

Head & Neck SCC Bempeg + VB10.NEO

Pancreatic Cancer Bempeg + BXCL701

Multiple Solid Tumors NKTR -262 + Bempeg

R/R NHL or Multiple Myeloma NKTR -255 (IL -15)

CD19 CAR -T NKTR -255 (IL -15)

Cancer Immunotherapy NKTR -255 (IL -15)

AA Registrational Study

Virology NKTR -255 (IL -15)

Partner Indication Program Preclinical Phase 1 Phase 2 Phase 3 NDA Filed

Registrational Study

Registrational Study

Registrational Study

Research Collaboration

Research CollaborationPain

Preview truncated — download the full document for the complete content.